Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr

Seuraava tapahtuma
2026 Q2 -tulosraportti 20.8.

Menneet tapahtumat
2026 Q1 -tulosraportti 21.5.
2025 Q4 -tulosraportti 26.3.
2025 Q3 -tulosraportti 19.11.2025
2025 Q2 -tulosraportti 15.8.2025
2025 Q1 -tulosraportti 8.5.2025

Asiakkaat katsoivat myös

Foorumi

Liity keskusteluun Nordnet Socialissa

Kirjaudu

Bagerbrød
8 t sitten
·
Bagerbrød
8 t sitten
·
Right now is probably an interesting learning project in connection with technical analysis!: There should be some resistance at 1,28! So how much will the price run up? To avoid falling below? Or does "one" expect today that the price will close below in any case? I can see that there is a lot of room to run within an intact trend channel (rising), so I believe that there will be a rather strong price increase before close today, as tomorrow's fall is above the resistance level at 1,28. With 1,75 as a kind of target, it is probably not unthinkable that the price goes far past 1,28! We'll see... There are 50 min. left.., And banks that themselves look at TA-curves can choose to enter now.., Exciting! Will 1,28 be breached today?
3D
6 t sitten
·
3D
6 t sitten
·
Friend, I am also holding onto my shares. That DNB Carnegie has started covering Bioporto is good for my portfolio. There have been almost 1 million trades, based on no other news than what DNB Carnegie has come out with, it could be because the bank is actively advising their clients to buy shares in Bioporto. The clients that DNB Carnegie advises are wealthy individuals who need to invest their money in shares. If it drops like a stone tomorrow, I believe it's the small shareholders who are taking profits home.
Preston20
14 t sitten
Preston20
14 t sitten
Fra DNB Carnegies POST-RESULTS NOTE * KDIGO guidelines likely the next trigger **Takeover a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. On our 2032 estimates we calculate this would imply a ~DKK4.7–5.6/share equity value (discounted by a 16.5% WACC). ***Fair value range of DKK0.5–3.0 per share reiterated. Our valuation range is based on a risk-adjusted SOTP NPV (16.5% WACC, 1.4x beta and 5% liquidity premium): The upper end reflects an additional 10% annual revenue growth and 1% annual EBITDA margin expansion from our forecast over 2026–44e; the lower end assumes no FDA approval of ProNephro for adults. - Q1 review DownloadQ1 revenue was slightly below our estimate, but we note good operational execution and cost control. The cash position as of 8 April was DKK98m. 2026 guidance was maintained. We expect KDIGO guidelines in H2, which we see as the next potential share price trigger. We make minor estimate changes and reiterate our FV range of DKK0.5–3.0 per share.
Preston20
11 t sitten
·
Preston20
11 t sitten
·
DNB Carnegie is one of the Nordic region's largest brokerage houses - their note is "right by the book" - professional and objective. Keep your insane conspiracies about stock market manipulation to yourself or report them! 3D wrote today: "My guess is that the stock is not rising fast enough in the bank's opinion, so therefore they are coming with this undocumented statement. I am actually not sure if it is entirely legal that they are trying to spread rumors about a purchase offer, which is not factual, but only rumors they themselves have invented."
3D
11 t sitten
·
3D
11 t sitten
·
Preston20 I hope you don't take it personally. I understand that you are the messenger, which I apparently have not written clearly enough. I agree that what they write is factually correct regarding the stock's value, which I also write. The following is for everyone, and not just you Preston. I would like to elaborate on my claim. I know for a fact that there are professionals who have gone to jail for hyping or pumping a stock, and/or received fines. There is a difference between us amateurs writing on Nordnet social, and as you write, a professional and very reputable bank writing an analysis. When a bank of this caliber writes something, there is weight behind it, and as we can all see, it affects the stock price. It has gone up 3,61% at the time of writing, because they have started a rumor that has no basis. Firstly, they have not clearly stated that it is a scenario they have set up, and that there is no basis for it. They have just come up with a sick narrative about a historical trend, which just strongly underlined the claim, and not a reservation. Secondly, they have also not clearly stated that this takeover bid must first go through the board and shareholders, and that they will most likely decline 3 kr. . If one reads their latest analysis, we can read that they were not satisfied that BP met guidance, because the bank itself had estimated higher, i.e., more earnings than the guidance. What is it that is illegal here. The bank starts a rumor that they themselves invented, because they historically know that the stock price will rise. They themselves have provided the smoking gun by writing in their analysis that they are disappointed that BP met guidance. If one of us, non-professionals, writes the same on Nordnet social, that there will be an acquisition, and has not attached a link, it will not affect the stock. But when a bank does it, of this caliber, it sends the stock soaring. which has also happened. In Denmark, it is illegal to pump a stock up or down for one's own gain. If a report is to be made to the financial supervisory authority, it must be those persons who bought based on the bank's analysis. who spend energy on it.
Bagerbrød
1 päivä sitten
·
Bagerbrød
1 päivä sitten
·
Simply Wall Street has on May 19 published an article with three promising European penny stocks. BioPorto is one of them.
Soegaard_Invest
1 t sitten
·
Soegaard_Invest
1 t sitten
·
Look, now it's also starting to become interesting for the Americans to follow little Danish Bioporto a bit. There are more and more small nascent signs that interest in the field is finally quietly and steadily establishing itself. I still believe in a somewhat higher share price, preferably north of 4 kr over the next couple of years, but I fear that Roche "steals" the company before then at a lower share price, what should actually stop them from making an offer most of us can't say no to?
3D
3 päivää sitten
·
3D
3 päivää sitten
·
BioPorto (Investment case): Q1 2026, advancement on the three pillars central to the long-term potential https://www.inderes.dk/en/research/bioporto-investment-case-q1-2026-advancement-on-the-three-pillars-central-to-the-long-term-potential?utm_source=nordnet&utm_medium=integration
3D
1 päivä sitten
·
3D
1 päivä sitten
·
John Kellum is co-chairman at KDIGO, and his words carry great weight with KDIGO's constituents, and he has stated that AKI should have a strong recommendation after cardiac surgery. A strong recommendation is a 1st degree recommendation. John Kellum has used Bioporto's NGAL test in his research. John Kellum has evidence that Bioporto's NGAL test saves lives after cardiac surgery. Furthermore, John Kellum has also just received an honorable award for his work with the above. Just for the sake of good order, if you want proof that John Kellum has used the NGAL test, you can just read through the documents I previously attached as a link to you. But since you are not aware that it is as certain as amen in church that Bioporto will receive a strong recommendation (1st degree recommendation), then you haven't read it, have you. https://www.linkedin.com/in/john-kellum-306b692b1/recent-activity/all/?trk=eml-email_next_best_action_digest_01-klgkMNTbQEuzEzzoxI2d1g%3D%3D-0-klgkMNTbQEuzEzzoxI2d1g%3D%3D
Overleif
1 päivä sitten
·
Overleif
1 päivä sitten
·
I honestly don't care about his foolish cheap prices, Research results are 1000 times more interesting. Well, let's hope for the strongest possible recommendation. We'll have to wait and see.
Bagerbrød
22.5.
·
Bagerbrød
22.5.
·
Just want to note that BP's increases historically have been driven by hysteria! These days/weeks/month(s) something "calmly" increasing is happening. And that, I think, is a sign of health. It doesn't jump by, for example, 75 øre. It seems to ground itself a bit à la two steps forward and one back. It looks calmer. It looks promising. Regards. Bagerbrød
Bagerbrød
22.5.
·
Bagerbrød
22.5.
·
What could I possibly mean by "gently rising"?
Bagerbrød
22.5.
·
Bagerbrød
22.5.
·
Thanks and likewise 😊🐾

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q1 -tulosraportti

5 päivää sitten

Uutiset

Kaikki uutiset